625 related articles for article (PubMed ID: 29129576)
1. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study.
Hundemer GL; Curhan GC; Yozamp N; Wang M; Vaidya A
Lancet Diabetes Endocrinol; 2018 Jan; 6(1):51-59. PubMed ID: 29129576
[TBL] [Abstract][Full Text] [Related]
2. Incidence of Atrial Fibrillation and Mineralocorticoid Receptor Activity in Patients With Medically and Surgically Treated Primary Aldosteronism.
Hundemer GL; Curhan GC; Yozamp N; Wang M; Vaidya A
JAMA Cardiol; 2018 Aug; 3(8):768-774. PubMed ID: 30027227
[TBL] [Abstract][Full Text] [Related]
3. Time-Dependent Risk of Atrial Fibrillation in Patients With Primary Aldosteronism After Medical or Surgical Treatment Initiation.
Kim KJ; Hong N; Yu MH; Lee H; Lee S; Lim JS; Rhee Y
Hypertension; 2021 Jun; 77(6):1964-1973. PubMed ID: 33866798
[TBL] [Abstract][Full Text] [Related]
4. Renin as a Biomarker to Guide Medical Treatment in Primary Aldosteronism Patients. Findings from the SPAIN-ALDO Registry.
Parra Ramírez P; Martín Rojas-Marcos P; Paja Fano M; González-Boillos M; Pascual-Corrales E; García Cano AM; Ruiz-Sanchez JG; Vicente Delgado A; Gómez Hoyos E; Ferreira R; García Sanz I; Recasens Sala M; Barahona San Millan R; Picón César MJ; Díaz Guardiola P; Perdomo CM; Manjón-Miguélez L; Rebollo Román Á; Robles Lázaro C; Morales-Ruiz M; Calatayud M; Andree Furio Collao S; Meneses D; Sampedro-Nuñez MA; Mena Ribas E; Sanmartín Sánchez A; Gonzalvo Diaz C; Lamas C; Guerrero-Vázquez R; Del Castillo Tous M; Serrano Gotarredona J; Michalopoulou Alevras T; Tenés Rodrigo S; Roa Chamorro R; Jaen Aguila F; Moya Mateo EM; Hanzu FA; Araujo-Castro M
High Blood Press Cardiovasc Prev; 2024 Jan; 31(1):43-53. PubMed ID: 38225508
[TBL] [Abstract][Full Text] [Related]
5. Association of cardiovascular disease risk and changes in renin levels by mineralocorticoid receptor antagonists in patients with primary aldosteronism.
Nomura M; Kurihara I; Itoh H; Ichijo T; Katabami T; Tsuiki M; Wada N; Yoneda T; Sone M; Oki K; Yamada T; Kobayashi H; Tamura K; Ogawa Y; Inagaki N; Yamamoto K; Otsuki M; Yabe D; Izawa S; Takahashi Y; Suzuki T; Yasoda A; Tanabe A; Naruse M;
Hypertens Res; 2022 Sep; 45(9):1476-1485. PubMed ID: 35764671
[TBL] [Abstract][Full Text] [Related]
6. Risk of new-onset diabetes mellitus in primary aldosteronism: a population study over 5 years.
Wu VC; Chueh SJ; Chen L; Chang CH; Hu YH; Lin YH; Wu KD; Yang WS;
J Hypertens; 2017 Aug; 35(8):1698-1708. PubMed ID: 28661412
[TBL] [Abstract][Full Text] [Related]
7. Long-term mortality and cardiovascular events in patients with unilateral primary aldosteronism after targeted treatments.
Wu VC; Wang SM; Huang KH; Tsai YC; Chan CK; Yang SY; Lin LY; Chang CC; Lu CC; Lin YH; Chen YM; Chueh JS
Eur J Endocrinol; 2021 Dec; 186(2):195-205. PubMed ID: 34851859
[TBL] [Abstract][Full Text] [Related]
8. Renal Outcomes in Medically and Surgically Treated Primary Aldosteronism.
Hundemer GL; Curhan GC; Yozamp N; Wang M; Vaidya A
Hypertension; 2018 Sep; 72(3):658-666. PubMed ID: 29987110
[TBL] [Abstract][Full Text] [Related]
9. The Spectrum of Subclinical Primary Aldosteronism and Incident Hypertension: A Cohort Study.
Brown JM; Robinson-Cohen C; Luque-Fernandez MA; Allison MA; Baudrand R; Ix JH; Kestenbaum B; de Boer IH; Vaidya A
Ann Intern Med; 2017 Nov; 167(9):630-641. PubMed ID: 29052707
[TBL] [Abstract][Full Text] [Related]
10. Influence of Different Treatment Strategies on New-Onset Atrial Fibrillation Among Patients With Primary Aldosteronism: A Nationwide Longitudinal Cohort-Based Study.
Pan CT; Liao CW; Tsai CH; Chen ZW; Chen L; Hung CS; Liu YC; Lin PC; Chang CC; Chang YY; Wu VC; Lin YH;
J Am Heart Assoc; 2020 Mar; 9(5):e013699. PubMed ID: 32070205
[TBL] [Abstract][Full Text] [Related]
11. Association of aldosterone and blood pressure with the risk for cardiovascular events after treatments in primary aldosteronism.
Haze T; Hirawa N; Yano Y; Tamura K; Kurihara I; Kobayashi H; Tsuiki M; Ichijo T; Wada N; Katabami T; Yamamoto K; Oki K; Inagaki N; Okamura S; Kai T; Izawa S; Yamada M; Chiba Y; Tanabe A; Naruse M
Atherosclerosis; 2021 May; 324():84-90. PubMed ID: 33831673
[TBL] [Abstract][Full Text] [Related]
12. Surgery decreases the long-term incident stroke risk in patients with primary aldosteronism.
Chang YH; Chung SD; Wu CH; Chueh JS; Chen L; Lin PC; Lin YH; Huang KH; Wu VC; Chu TS;
Surgery; 2020 Feb; 167(2):367-377. PubMed ID: 31676114
[TBL] [Abstract][Full Text] [Related]
13. Association of Reversal of Renin Suppression With Long-Term Renal Outcome in Medically Treated Primary Aldosteronism.
Katsuragawa S; Goto A; Shinoda S; Inoue K; Nakai K; Saito J; Nishikawa T; Tsurutani Y
Hypertension; 2023 Sep; 80(9):1909-1920. PubMed ID: 37449450
[TBL] [Abstract][Full Text] [Related]
14. Mineralocorticoid Receptor Antagonist Effect on Aldosterone to Renin Ratio in Patients With Primary Aldosteronism.
Pecori A; Buffolo F; Burrello J; Mengozzi G; Rumbolo F; Avataneo V; D'Avolio A; Rabbia F; Bertello C; Veglio F; Mulatero P; Monticone S
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3655-e3664. PubMed ID: 33942084
[TBL] [Abstract][Full Text] [Related]
15. Risk of new-onset autoimmune diseases in primary aldosteronism: a nation-wide population-based study.
Er LK; Chen L; Tsai YC; Lin YH; Huang WC; Chang CC; Lu CC; Huang KH; Chueh JS; Wu KD; Wu VC;
J Hypertens; 2020 Apr; 38(4):745-754. PubMed ID: 31764584
[TBL] [Abstract][Full Text] [Related]
16. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
17. Mortality in Patients With Primary Aldosteronism: A Swedish Nationwide Study.
Gkaniatsa E; Zverkova Sandström T; Rosengren A; Trimpou P; Olsson DS; Lind M; Muth A; Johannsson G; Ragnarsson O
Hypertension; 2023 Dec; 80(12):2601-2610. PubMed ID: 37855142
[TBL] [Abstract][Full Text] [Related]
18. Outcome of adrenal vein sampling performed during concurrent mineralocorticoid receptor antagonist therapy.
Haase M; Riester A; Kröpil P; Hahner S; Degenhart C; Willenberg HS; Reincke M
J Clin Endocrinol Metab; 2014 Dec; 99(12):4397-402. PubMed ID: 25222758
[TBL] [Abstract][Full Text] [Related]
19. Adrenalectomy Lowers Incident Atrial Fibrillation in Primary Aldosteronism Patients at Long Term.
Rossi GP; Maiolino G; Flego A; Belfiore A; Bernini G; Fabris B; Ferri C; Giacchetti G; Letizia C; Maccario M; Mallamaci F; Muiesan ML; Mannelli M; Negro A; Palumbo G; Parenti G; Rossi E; Mantero F;
Hypertension; 2018 Apr; 71(4):585-591. PubMed ID: 29483224
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis.
Monticone S; D'Ascenzo F; Moretti C; Williams TA; Veglio F; Gaita F; Mulatero P
Lancet Diabetes Endocrinol; 2018 Jan; 6(1):41-50. PubMed ID: 29129575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
